Patents by Inventor Constantin Van Outryve d'Ydewalle

Constantin Van Outryve d'Ydewalle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES
    Publication number: 20240011029
    Abstract: Oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use against Alzheimer disease and other tauopathies are disclosed.
    Type: Application
    Filed: September 26, 2022
    Publication date: January 11, 2024
    Inventors: Andreas EBNETH, Constantin VAN OUTRYVE D'YDEWALLE, Sergei GRYAZNOV, Saúl MARTINEZ MONTERO, Leonid BEIGELMAN, Vivek Kumar RAJWANSHI
  • Modified oligonucleotides for use in treatment of tauopathies
    Patent number: 11453881
    Abstract: Oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use against Alzheimer disease and other tauopathies are disclosed.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 27, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Andreas Ebneth, Constantin Van Outryve D'Ydewalle, Sergei Gryaznov, Saúl Martinez Montero, Leonid Beigelman, Vivek Kumar Rajwanshi
  • Combinations for the modulation of SMN expression
    Patent number: 11198867
    Abstract: Certain embodiments are directed to methods and compounds for modulating expression of SMN. In certain embodiments at least two compounds are used: a first compound for inhibiting SMN-NAT and increasing expression of SMN, and a second compound for modulating the splicing of SMN. Such methods and compounds are useful for increasing expression exon 7 containing SMN mRNA in cells and animals.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 14, 2021
    Assignees: Ionis Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Frank Rigo, C. Frank Bennett, Constantin Van Outryve D'Ydewalle, Charlotte J. Sumner
  • MODIFIED OLIGONUCLEOTIDES FOR USE IN TREATMENT OF TAUOPATHIES
    Publication number: 20210095284
    Abstract: Oligonucleotides comprising modifications at the 2 and/or 3? positions(s) along with methods of making and use against Alzheimer disease and other tauopathies are disclosed.
    Type: Application
    Filed: March 13, 2019
    Publication date: April 1, 2021
    Inventors: Andreas EBNETH, Constantin VAN OUTRYVE D'YDEWALLE, Sergei GRYAZNOV, Saúl MARTINEZ MONTERO, Leonid BEIGELMAN, Vivek Kumar RAJWANSHI
  • Modulation of SMN expression
    Patent number: 10851371
    Abstract: Certain embodiments are directed to methods and compounds for inhibiting SMN-NAT, the natural antisense transcript of SMN. Such methods and compounds are useful for increasing expression of SMN in cells and animals.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: December 1, 2020
    Assignees: Ionis Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Frank Rigo, C. Frank Bennett, Constantin Van Outryve D'Ydewalle, Charlotte J. Sumner
  • COMBINATIONS FOR THE MODULATION OF SMN EXPRESSION
    Publication number: 20200308580
    Abstract: Certain embodiments are directed to methods and compounds for modulating expression of SMN. In certain embodiments at least two compounds are used: a first compound for inhibiting SMN-NAT and increasing expression of SMN, and a second compound for modulating the splicing of SMN. Such methods and compounds are useful for increasing expression exon 7 containing SMN mRNA in cells and animals.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 1, 2020
    Applicants: Ionis Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Frank Rigo, C. Frank Bennett, Constantin Van Outryve D'Ydewalle, Charlotte J. Sumner
  • MODULATION OF SMN EXPRESSION
    Publication number: 20180273943
    Abstract: Certain embodiments are directed to methods and compounds for inhibiting SMN-NAT, the natural antisense transcript of SMN.
    Type: Application
    Filed: April 11, 2016
    Publication date: September 27, 2018
    Applicants: Ionis Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Frank Rigo, C. Frank Bennett, Constantin Van Outryve D'Ydewalle, Charlotte J. Sumner
  • HDAC inhibitors to treat charcot-marie-tooth disease
    Patent number: 9238028
    Abstract: The disclosure relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, such as Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: January 19, 2016
    Assignees: VIB VZW, Life Sciences Research Partners VZW
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
  • HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE
    Publication number: 20160000766
    Abstract: The present application relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, most particularly, Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Application
    Filed: September 16, 2015
    Publication date: January 7, 2016
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
  • HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE
    Publication number: 20140329849
    Abstract: The disclosure relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, such as Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 6, 2014
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht
  • HDAC INHIBITORS TO TREAT CHARCOT-MARIE-TOOTH DISEASE
    Publication number: 20130227717
    Abstract: The present application relates to diseases in the peripheral nervous system, particularly hereditary neuropathies, most particularly, Charcot-Marie-Tooth (CMT) disease. It is shown that this disease is associated with decreased acetylated tubulin levels, which can be overcome by inhibition of histone deacetylases (HDACs). Using HDAC inhibitors, it is shown herein that the symptoms of the CMT phenotype can be overcome both in vitro and in vivo. Also provided herein are two different mouse models of CMT disease.
    Type: Application
    Filed: October 6, 2011
    Publication date: August 29, 2013
    Applicant: Life Sciences Research Partners VZW
    Inventors: Ludo Van Den Bosch, Constantin Van Outryve d'Ydewalle, Wim Robberecht